ArticleBMC infectious diseases2018
Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients' data analysis for outcome and effectiveness of the current regimens.
Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Molecular epidemiology of M. tuberculosis in Ethiopia: A systematic review and meta-analysis.Tuberculosis (Edinburgh, Scotland) · 2019Pooled it
- Comparison of Patients Who Were Not Evaluated and Lost to Follow-Up with Multidrug/Rifampin-Resistant Tuberculosis in South Korea.Yonsei medical journal · 2025Article
- Treatment completion of drug-resistant tuberculosis in Ethiopia: A perspective from healthcare users.PLOS global public health · 2025Article
- Multidrug-resistant tuberculosis treatment outcomes and associated factors at Yirgalem General Hospital, Sidama Region, South Ethiopia: a retrospective cohort study.BMC pulmonary medicine · 2024Article
- Treatment outcomes of standardized injectable shorter regimen for multi-drugs resistant tuberculosis in Ethiopia: a retrospective cohort study.BMC infectious diseases · 2024Article
- Deep learning on longitudinal CT scans: automated prediction of treatment outcomes in hospitalized tuberculosis patients.iScience · 2023Article
- Article
- Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study.Infection and drug resistance · 2022Article
- Pragmatic Management of Drug-Resistant Tuberculosis: A Qualitative Analysis of Human Resource Constraints in a Resource-Limited Country context-Ethiopia.International journal of public health · 2021Article
- Article
- Predictors of mortality among multidrug-resistant tuberculosis patients in central Ethiopia: a retrospective follow-up study.Epidemiology and infection · 2020Article
- Article
- Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in Ethiopia.Scientific reports · 2019Article
- Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.BMC pharmacology & toxicology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe programmatic management of Multidrug-resistant tuberculosis (MDR-TB) is entirely based on a WHO recommended long-term, 18-24 month lasting treatment regimen. However, growing evidence shows that low treatment success rate and high rates of adverse events are associated with this regimen. Up to date, the MDR-TB treatment outcome is not sufficiently understood in Ethiopia. Therefore, this analysis aimed to determine the pooled estimates of successful (cure, completed, or both), and poor outcomes (death, failure, and lost to follow ups).
methodA systematic search was performed to identify eligible studies reporting MDR-TB treatment outcomes in Ethiopia. Relevant studies for our analysis were retrieved from PubMed database search, Google Scholar and institutional repository sites of Ethiopian universities up to March 15, 2018. The primary outcome was treatment success, referring to a composite of cure and treatment completion. A random effect model was used to calculate pooled estimates.
resultsSix studies reporting treatment outcome on the 1993 MDR-TB patients were included in this analysis. Of the cases, the 1288 and 442 patients had a successful and poor outcome, respectively. In the pooled analysis, treatment success was observed in 59.2% (95%CI, 48.1-70.4) of patients, while 23.3% (95%CI, 19.7-27.0%) of patients had a poor outcome. in sub-group analysis,46.1% (95%CI, 34.2-58.0) were cured, 12.8% (5.7-20.0) treatment completed, 14.3% (11.5-17.2) died, 7.5% (3.7-11.3) lost to follow up, and 1.6% (1.1-2.2%) experienced treatment failure. The 25.0% (14.6-35.5) patients whose treatment outcome was not assessed (on treatment or transfer-out).
conclusionThe result of this study highlight treatment success among MDR-TB is below acceptable range. To update the current treatment regimen, the levels of evidence need to be replicated through meticulous surveillance systems.
trial registrationStudy protocol registration: CRD42018090711 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.